Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05SHK
|
|||
| Former ID |
DAP000122
|
|||
| Drug Name |
Nadolol
|
|||
| Synonyms |
Anabet; Corgard; Corgaretic; Nadic; Nadololum; Solgol; SQ 11725; SQ11725; Anabet (TN); Corgard (TN); Corzide (TN); Nadololum [INN-Latin]; SQ-11725; Solgol (TN); Alti-Nadolol (TN); Apo-Nadol (TN); Novo-Nadolol (TN); Nadolol (JP15/USP/INN); Nadolol [USAN:BAN:INN:JAN]; (2R,3S)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol; 2,3-cis-1,2,3,4-Tetrahydro-5-((2-hydroxy-3-tert-butylamino)propoxy)-2,3-naphthalenediol; 5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-2,3-naphthalenediol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | High blood pressure [ICD-11: BA00; ICD-10: I10] | Approved | [1], [2] | |
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Company |
Apotex Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H27NO4
|
|||
| Canonical SMILES |
CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O
|
|||
| InChI |
1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1
|
|||
| InChIKey |
VWPOSFSPZNDTMJ-UCWKZMIHSA-N
|
|||
| CAS Number |
CAS 220045-89-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
855594, 7847498, 7980059, 8149963, 8175898, 10321209, 11335602, 11360841, 11364537, 11367099, 11369661, 11372751, 11373904, 11377823, 11461813, 11466846, 11467966, 11485128, 11486372, 11489362, 11491401, 11492008, 11495457, 12013396, 26612453, 26680146, 34705082, 46505509, 47216720, 47440192, 47515259, 48035045, 48110397, 48416301, 49995587, 50105273, 53787811, 56413054, 56422422, 57312272, 75643004, 85787107, 92124849, 92125681, 92307845, 99301515, 99351138, 103189209, 103913689, 104169962
|
|||
| ADReCS Drug ID | BADD_D01512 | |||
| SuperDrug ATC ID |
C07AA12
|
|||
| SuperDrug CAS ID |
cas=042200339
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-1 (ADRB1) | Target Info | Modulator | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Gap junction | ||||
| Salivary secretion | ||||
| Dilated cardiomyopathy | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta1 adrenergic receptor signaling pathway | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 554). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074229. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.